PCT Acquires New Technology for Hypochlorous Acid
PCT LTD (PCTL) has acquired rights to a novel delivery technology from Colorado-based Onza Corporation. This patent-pending technology allows PCT to convert hypochlorous acid into a dry crystal, simplifying shipping and extending shelf life significantly. The technology enhances cost-effectiveness and expands potential applications for unstable compounds like chlorine dioxide. PCT has secured exclusive rights for using crystallized hypochlorous acid and medical applications for crystallized chlorine dioxide, with market studies and cost analyses underway.
- Acquisition of a novel delivery technology enhancing shipping efficiency and shelf life of hypochlorous acid.
- Exclusive rights for applications in crystallized hypochlorous acid and medical applications for crystallized chlorine dioxide.
- Potential for expanding market opportunities and applications for chlorine dioxide and hypochlorous acid.
- None.
This new cost-cutting delivery method for efficacious but unstable compounds like chlorine dioxide and hypochlorous acid opens the door to several new uses and applications for these compounds while greatly expanding current markets. Without this technology, these compounds must be produced onsite for immediate use. The half-life of chlorine dioxide, for example, is short; depending on conditions, it may be as short as a few minutes.
Onza is a technology company based in
About
Forward-Looking Statements:
This press release contains "forward-looking statements" as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward-looking statements."
Such statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Such statements involve risks and uncertainties, including but not limited to: PCTL's ability to raise sufficient funds to satisfy its working capital requirements; the ability of PCTL to execute its business plan; the anticipated results of business contracts with regard to revenue; and any other effects resulting from the information disclosed above; risks and effects of legal and administrative proceedings and government regulation; future financial and operational results; competition; general economic conditions; and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements PCTL makes in this press release include market conditions and those set forth in reports or documents it files from time to time with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005994/en/
Investor Relations Contact
(760) 621-0062
Mike@MountaintopMedia.net
www.para-con.com
www.pctcorphealth.com
Twitter: https://mobile.twitter.com/PCTL_
Source:
FAQ
What technology has PCT LTD acquired?
What is the significance of the acquisition for PCTL?
What exclusive rights has PCT LTD secured through this acquisition?